Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PentiMyelo: [68Ga]Ga-PentixaFor PET in Multiple Myeloma
NCT04561492Phase 2Active, not recruiting
- Sponsor
- CHU de Nantes
- Start
- Sep 2021
- Primary completion
- Dec 2029
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pentixafor in multiple myeloma (MM), sponsored by CHU de Nantes. Primary endpoint: Sensitivity of [68Ga]Ga-PentixaFor-PET to detect Multiple Myeloma lesions at 1 Month. Started Sep 2021; status: active, not recruiting.
02
Drugs
pentixafor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04561492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04561492.